Rethinking of neoadjuvant therapy for patients with initially resectable colorectal cancer liver metastases
10.3760/cma.j.cn113884-20200507-00249
- VernacularTitle:初始可切除结直肠癌肝转移新辅助化疗的再思考
- Author:
Gong CHEN
1
;
Yuhong LI
;
Rongxin ZHANG
;
Binkui LI
;
Fulong WANG
;
Yunfei YUAN
;
Zhizhong PAN
;
Desen WAN
Author Information
1. 中山大学肿瘤医院结直肠科，广州 510060
- From:
Chinese Journal of Hepatobiliary Surgery
2020;26(7):488-492
- CountryChina
- Language:Chinese
-
Abstract:
Surgical resection is the best method for patients with colorectal cancer liver metastases. However, tumor recurrence rate is still high after surgery. Preoperative chemotherapy can help shrink the tumor, test biological behavior, and reduce recurrence rate; but it may also cause liver injury and delay surgery. There is still controversy whether neoadjuvant chemotherapy should be performed and how to select patients from chemotherapy before surgery. Thus, in this article, combined the research progress and the clinical experience of author's center, we discuss this issue in 4 aspects: the development of neoadjuvant chemotherapy; the indications and guideline recommendation for neoadjuvant chemotherapy; the selection of neoadjuvant chemotherapy regimens; common problems in neoadjuvant chemotherapy.
